BioCentury
ARTICLE | Clinical News

RM-131: Phase II started

June 11, 2012 7:00 AM UTC

Rhythm began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 10-100 µg subcutaneous RM-131 for 35 days in about 125 patients with Type I and Type II diabetes. Rhythm has exclusive,...